Company Overview

BioAge Labs, Inc. (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases by targeting the biological mechanisms of aging. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on obesity, cardiometabolic disease, and related chronic conditions. BioAge’s strategy combines human longevity datasets, biomarker discovery, and drug development to identify molecular pathways associated with aging that may influence metabolic health and disease progression.

The company’s primary revenue and value drivers are tied to the advancement of its therapeutic pipeline, research collaborations, and intellectual property portfolio rather than commercial product sales, as BioAge remains in the clinical development stage. BioAge was founded in 2015 and evolved from research leveraging longitudinal human aging datasets designed to identify biological pathways associated with healthy aging and disease risk. Its positioning is differentiated by its integration of computational biology, human cohort data, and drug development capabilities aimed at translating aging science into therapeutics for obesity and metabolic disorders.

Business Operations

BioAge conducts its operations primarily through integrated drug discovery and clinical development activities. Its business is centered on advancing internally developed and in-licensed therapeutic candidates targeting pathways linked to appetite regulation, muscle preservation, and metabolic function. The company’s lead programs have included therapies directed toward obesity and cardiometabolic disease mechanisms, with development activities supported through biomarker-driven patient selection and translational biology platforms. BioAge’s operations are primarily based in the United States, with clinical development activities extending through external research organizations and trial networks.

The company controls a portfolio of proprietary biological datasets, computational discovery capabilities, and licensed therapeutic assets. BioAge has entered into strategic licensing and collaboration arrangements involving pharmaceutical compounds and development programs, including agreements associated with metabolic and obesity-focused therapies. The company’s operational model relies heavily on research partnerships, outsourced manufacturing, and clinical trial management relationships common among clinical-stage biotechnology firms. Public filings indicate the company has focused investment on pipeline advancement, platform development, and regulatory preparation activities.

Strategic Position & Investments

BioAge’s strategic direction is centered on developing therapies that address obesity and metabolic diseases through mechanisms associated with aging biology. The company has emphasized advancing clinical-stage assets while expanding its discovery platform to identify additional therapeutic targets linked to longevity and metabolic resilience. Its growth initiatives have included clinical trial progression, expansion of biomarker-driven drug development capabilities, and leveraging human aging datasets to support target validation and patient stratification.

The company has pursued acquisitions and licensing arrangements primarily through asset-focused transactions rather than large-scale corporate acquisitions. BioAge has disclosed investments in therapeutic candidates and research programs involving metabolic regulation, neurobiology, and aging-associated pathways. The company’s broader strategic positioning reflects growing pharmaceutical industry interest in obesity therapeutics and age-related disease interventions, particularly in areas where metabolic health, muscle function, and longevity science intersect.

Geographic Footprint

BioAge is headquartered in Richmond, California, and its principal operational footprint is concentrated in the United States. The company conducts research, clinical development, and corporate activities domestically while utilizing global clinical research infrastructure and third-party development partners where necessary. Its operational presence reflects the typical structure of a clinical-stage biotechnology company, with centralized headquarters functions supported by distributed research and clinical activities.

Although BioAge does not maintain the extensive international commercial infrastructure associated with large pharmaceutical companies, its development programs and intellectual property strategy position it within the broader global biotechnology ecosystem. The company participates in international scientific collaborations and may engage clinical trial sites and manufacturing partners across multiple regions depending on program requirements and regulatory considerations.

Leadership & Governance

BioAge was co-founded by Kristen Fortney, who has played a central role in shaping the company’s scientific and strategic direction. The company’s leadership philosophy has emphasized data-driven drug discovery, translational aging biology, and the application of human longitudinal datasets to therapeutic development. Public disclosures and executive communications have consistently highlighted a strategy focused on linking aging mechanisms to major unmet medical needs in obesity and cardiometabolic disease.

Key members of leadership have included:

• Kristen Fortney – Chief Executive Officer and Co-Founder
• Mark Gurney – President and Chief Scientific Officer
• Erik van der Veer – Co-Founder
• Christopher Hite – Chief Financial Officer

BioAge’s governance structure follows standard public biotechnology company practices, including oversight by a board of directors and compliance frameworks outlined in SEC filings and public corporate governance disclosures. Data regarding certain executive roles and committee structures may change over time based on company filings and reporting updates.